{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 1', 'Study Schematic', '52 weeks', 'Up to 28', 'Placebo (n=50)', 'days', 'Follow-up2', 'Screening', 'R', 'Danirixin, 35mg', '(n=50)', ': If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2 Follow-up visit to occur within 28days of last dose of study medication', 'Section 6.1', 'Inclusion Criteria', 'Original text:', '2. Male or female', 'g.', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'h. Female participants:', 'A female participant is eligible to participate if she is not pregnant (see Section 12.5;', 'Appendix 5), not breastfeeding, and at least one of the following conditions applies:', 'i. Not a woman of childbearing potential (WOCBP) as defined in Section 12.5', '(Appendix 5)', 'OR', 'ii. A WOCBP who agrees to follow the contraceptive guidance in Section 12.5', '(Appendix 5) during the treatment period and for at least 60 hours after the', 'last dose of study treatment.', '86']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Revised text:', '3. Male or female', 'i.', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'j. Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', '87']['2016N293064_01', 'CONFIDENTIAL', '2018N394263_00', '-', '205864', 'Section 12.2 Appendix 2:', 'Original text:', 'Table 7', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as', 'needed for women of childbearing potential\u00b2\u00b2', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody\u00b3', 'All study-required laboratory assessments will be performed by a central', 'laboratory, with the exception of urine testing', '88']\n\n###\n\n", "completion": "END"}